RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

Original reporting
Published Nov 13, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 2:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GLSI
Bullish
high confidence
Mentioned
$GLSI
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$GLSIBullishMed
01

Why it matters

The disclosed Phase III data could accelerate FDA review and expand the addressable patient pool, influencing valuation.

02

Market read

First report of strong Phase III results for a micro‑cap biotech, likely to move the stock and related sector.

03

What to watch

Manufacturing scale‑up risks and competition from other HER2‑targeted therapies.

Relevance 8/10Novelty 8/10Timing: today

Background

Greenwich LifeSciences (GLSI) is a clinical‑stage biotech focusing on immunotherapy for HER2‑positive breast cancer.

Company-level read

Ticker impact

$GLSIBullishHigh confidence
Context

First public disclosure of Phase III trial data showing ~80% reduction in breast cancer recurrence.

Expected impact

likely upward pressure as market prices in the encouraging Phase III data.

Evidence & confidence

Phase III data is material for a clinical‑stage biotech; first report of such magnitude typically drives price gains.

Market effects

May boost sentiment for immunotherapy and breast‑cancer biotech peers.

US biotech sector could see modest gains; European sites may follow as trial sites expand.

Highlights US‑Europe collaboration in oncology trials, potentially attracting global investors.

Counterpoint

Skeptics may question durability of early Phase III results and regulatory timelines.

Key entities

  • Greenwich LifeSciences, Inc.

    Developer of GLSI-100 immunotherapy.

  • RedChip Companies, Inc.

    Investor‑relations firm arranging the interview.

Related articles

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.

$GLSIMedAI 8/10

Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes

Greenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.